The Hunter Medical Research Institute (HMRI) has taken its commitment to medical research innovation to the international stage, with representatives attending Clinical Trials Festival Asia 2025 in March.

Now in its third year, the event has become a premier gathering for clinical research professionals, fostering collaboration among global experts to shape the future of medical trials. Asia is playing an increasingly crucial role in this space, with Singapore, South Korea, and Australia leading the way in innovation, regulatory frameworks, and trial efficiency.

Clinical trials drive medical progress, yet many promising studies face challenges in funding, recruitment, and real-world application. Establishing the right connections can determine whether a breakthrough reaches patients or remains unrealised. Associate Professor Nicolette Hodyl, Chief of Research Translation and Healthcare Improvement, and Jennifer Holland, Business Development Manager, represented HMRI at the conference. They contributed to discussions on accelerating research translation, removing barriers, and ensuring life-changing treatments reach those who need them most. The event provided a unique platform to share impactful stories, explore emerging trial designs, and shape global best practices.

Reflecting on the experience, Associate Professor Hodyl said, “This conference allowed us to share the world-class expertise and capability we have at HMRI in designing and delivering clinical trials with international leaders, and discuss opportunities for bringing novel trials to our region to improve health outcomes for our community”

Jennifer Holland shared insights on the festival’s impact, stating that ” attending the festival alongside Investment NSW was a fantastic opportunity to explore the role of artifical intelligence (AI) in transforming clinical trials. We gained valuable insights, fored new connections, and strengthened HMRI’s global impact to drive innovation in the Hunter region”.

The future of clinical trials in the Asia-Pacific

The conference highlighted the Asia-Pacific region’s growing prominence as a clinical trials hub, with a focus on enhancing trial efficiency and innovation. Key discussions covered patient recruitment and engagement challenges, the role of biomarkers in trial design, and advancements in medical affairs and immunology. The event also celebrated industry excellence with the Asia Pacific Bioprocessing Excellence Awards.

The second day turned to pre-clinical research and its transition into clinical trials. Experts examined the rise of decentralised and multi-centre trials, which improve accessibility and streamline processes. A roundtable discussion brought together leaders to analyse the clinical trial pathway, from drug discovery to regulatory approval and patient-centred care. The conference concluded with insights into emerging modalities and innovations shaping oncology trials.

Advancing clinical trials in the Hunter New England region

HMRI is committed to clinical trials as part of its ambitions to create the healthiest million people on the planet. Through partnerships with researchers, clinicians, and industry leaders, HMRI is working to ensure that every person in the Hunter New England region has access to trials that enhance health outcomes.

The region is uniquely positioned for clinical trial success, boasting a diverse population, a strong medical research ecosystem, and world-class health infrastructure, including the approaching John Hunter Health and Innovation Precinct.

HMRI’s Clinical Trials Unit continues to expand its capabilities, enhancing access to trial sites and leveraging expertise in data sciences and health economics. With significant support from the NSW Government, including an $835 million investment in the John Hunter Health and Innovation Precinct, HMRI is shaping the future of clinical research in the Hunter New England region and beyond.

Clinical trial partnership opportunities

HMRI collaborates with industry partners, including pharmaceutical and medical technology companies, to advance drug discovery and development. These clinical trial partners benefit from access to a world-class health system, rapid approvals, and a globally significant research ecosystem. For those looking to conduct clinical trials, HMRI provides the expertise, infrastructure, and diverse population needed to accelerate medical breakthroughs.

---

Contact the HMRI Clinical Trials Unit to explore partnership opportunities and contribute to improving global health outcomes.